Charles Schwab Investment Management Inc. Boosts Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Charles Schwab Investment Management Inc. boosted its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 142.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 165,929 shares of the company's stock after purchasing an additional 97,362 shares during the period. Charles Schwab Investment Management Inc. owned 0.56% of Dianthus Therapeutics worth $4,543,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of DNTH. Great Point Partners LLC lifted its holdings in shares of Dianthus Therapeutics by 21.3% during the second quarter. Great Point Partners LLC now owns 757,929 shares of the company's stock worth $19,615,000 after purchasing an additional 132,929 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Dianthus Therapeutics by 860.5% in the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company's stock valued at $2,095,000 after buying an additional 72,509 shares during the period. Rhumbline Advisers bought a new position in shares of Dianthus Therapeutics during the second quarter worth about $832,000. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Dianthus Therapeutics by 281.9% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company's stock worth $1,022,000 after acquiring an additional 29,159 shares during the period. Finally, Point72 DIFC Ltd bought a new stake in Dianthus Therapeutics in the second quarter valued at approximately $334,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Stock Up 1.3 %

DNTH stock traded up $0.31 during midday trading on Friday, reaching $23.81. 113,847 shares of the company's stock traded hands, compared to its average volume of 205,775. Dianthus Therapeutics, Inc. has a 52 week low of $6.58 and a 52 week high of $33.77. The company has a market cap of $704.78 million, a price-to-earnings ratio of -9.52 and a beta of 1.74. The firm's fifty day moving average price is $26.09 and its 200-day moving average price is $26.57.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Raymond James upgraded shares of Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Finally, Oppenheimer lifted their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, November 11th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of "Buy" and an average target price of $46.43.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.